Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KONFIDENT-S open-label extension of oral KVD900 for hereditary angioedema attacks
NL-OMON56365Phase 3Recruiting
- Sponsor
- KalVista Pharmaceuticals
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sebetralstat in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2), sponsored by KalVista Pharmaceuticals. Primary endpoint: Proportion of patients with at least one adverse event. Started Jul 2023; status: recruiting.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on NL-OMON56365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56365.